Abstract
Recent population-based studies suggest that the incidence of advanced and metastatic prostate cancer may be increasing. Concurrently with this apparent stage migration toward advanced disease, several major developments have occurred in the treatment paradigm for men with advanced prostate cancer. These include the US Food and Drug Administration approval of 8 novel agents over the last decade. In addition to novel pharmaceuticals, rapidly evolving diagnostic tools have emerged. This review provides a primer for clinicians who treat men with advanced prostate cancer, including medical oncologists, radiation oncologists, and urologists.
| Original language | English |
|---|---|
| Pages (from-to) | 108-118 |
| Number of pages | 11 |
| Journal | Clinical Advances in Hematology and Oncology |
| Volume | 19 |
| Issue number | 2 |
| State | Published - Feb 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Advanced prostate cancer
- Anti-androgen
- Castration- resistant
- Castration-sensitive
- Prostate cancer
- Prostate-specific membrane antigen
Fingerprint
Dive into the research topics of 'Contemporary management of advanced prostate cancer: An evolving landscape'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver